Propofol Use in Pediatric Patients With Food Allergy and Eosinophilic Esophagitis

Pooja Mehta1, Shikha S Sundaram, Glenn T Furuta

  • 1*Digestive Health Institute †Gastrointestinal Eosinophilic Diseases Program, Digestive Health Institute ‡Department of Biostatistics §Gastrointestinal Eosinophilic Diseases Program, Section of Allergy and Immunology ¶Department of Anesthesiology, Children's Hospital Colorado, University of Colorado, School of Medicine, Aurora, CO.

Insights

Propofol is safe for children with eosinophilic esophagitis (EoE) and food allergies, despite contraindications. This study found no increased complications when propofol was used in these pediatric patients.

Area of Science:

  • Anesthesiology
  • Pediatric Gastroenterology
  • Allergy and Immunology

Background:

  • Propofol, a common anesthetic, carries a contraindication for patients with egg or soy allergies.
  • Rising rates of food allergies and eosinophilic esophagitis (EoE) present challenges to this contraindication.
  • Clinical practice regarding propofol use in pediatric patients with these allergies requires investigation.

Purpose of the Study:

  • To examine the utilization of propofol for esophagogastroduodenoscopies in children with EoE and food allergies.
  • To assess the safety and complication rates associated with propofol use in this specific pediatric population.

Main Methods:

  • Retrospective observational study of 1365 esophagogastroduodenoscopies.
  • Data collected from January 2013 to June 2014.
  • Statistical analysis included Student t tests, chi-square tests, Fisher exact tests, and multivariable logistic regression.

Main Results:

  • Propofol was administered less frequently to patients with egg or soy allergy and those with EoE.
  • This reduced usage persisted even after accounting for the presence of food allergies.
  • No significant difference in complication rates was observed between patients who received propofol and those who did not.

Conclusions:

  • Propofol can be safely administered to pediatric patients with EoE and food allergies.
  • The study suggests that the contraindication may be overly cautious in this patient group.
  • Further single-center review indicates propofol is a safe option for these children.

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
893
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
652
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
698
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
2.0K